WEBINAR | ON-DEMAND
Helping Patients Afford Medications Using the 340B Program and Other Tools
On-demand
Originally aired on August 20, 2026
Originally aired on August 20, 2026
January 21, 2026 at 1:00 pm (EDT)
Webinar Information
This webinar is included in the 2026 Annual Compliance Training Subscription.
Overview
Learning Objectives
Audience
Instructors
Format
Helping Patients Afford Medications Using the 340B Program and Other Tools
Health centers manage the health of their patients, including by prescribing drugs or helping patients fill prescriptions. Too often, patients encounter affordability issues at the pharmacy counter, whether because they are uninsured or have a high cost-sharing obligation. Though health centers might want to deploy resources to help their patients obtain their prescribed medication, state and federal fraud and abuse laws including the antikickback statute and patient inducement civil monetary penalty can create risk for well-intentioned actions. In addition, health centers are required to ensure that low-income patients who are uninsured or who have substantial cost-sharing obligations receive injectable epinephrine and insulin at discounted prices. HRSA has also announced that the 340B discount for some commonly-prescribed drugs will only be available as a rebate in 2027, further complicating health centers’ ability to provide point-of-sale discounts to patients.
This session describes the challenges inherent in helping patients afford their medication and discusses strategies for complying with Notice of Award terms and assisting patients without triggering compliance risks.
Health centers manage the health of their patients, including by prescribing drugs or helping patients fill prescriptions. Too often, patients encounter affordability issues at the pharmacy counter, whether because they are uninsured or have a high cost-sharing obligation. Though health centers might want to deploy resources to help their patients obtain their prescribed medication, state and federal fraud and abuse laws including the antikickback statute and patient inducement civil monetary penalty can create risk for well-intentioned actions. In addition, health centers are required to ensure that low-income patients who are uninsured or who have substantial cost-sharing obligations receive injectable epinephrine and insulin at discounted prices. HRSA has also announced that the 340B discount for some commonly-prescribed drugs will only be available as a rebate in 2027, further complicating health centers’ ability to provide point-of-sale discounts to patients.
This session describes the challenges inherent in helping patients afford their medication and discusses strategies for complying with Notice of Award terms and assisting patients without triggering compliance risks.
- Pharmacy Managers
- Risk Managers
- Compliance Officers
- COOs
- CEOs
- CFOs
- Executive Leadership
- Identify the potential risks of providing patients with financial assistance outside of a structured policy, including under the rebate model that will begin in 2027.
- Compare strategies for providing patient assistance.
- Implement an insulin/injectable epinephrine policy that complies with Notice of Award requirements.
Jason Reddish
Joella Roland
Principal
Jason has focused primarily on the 340B Program for the past 13-plus years, representing community health centers, Ryan White HIV/AIDS clinics, and STD program grantees primarily for the past 8 years. His time is split nearly evenly among transactions, compliance, remedial action, and advocacy for covered entity protections at the state and federal level.
- This is a 60-minute webinar session.
- The session was recorded and is available on-demand.
- This webinar is included with the 2026 Annual Compliance Training Subscription.
Quick links
Resources
Join our mailing list
Be the first to know about new content and training products!
Thank you!
© 2026 Powers Pyles Sutter & Verville PC. All rights reserved.
